目的　探讨细胞间隙连接蛋白 4 3(CX4 3)与上皮性卵巢癌化疗疗效 (耐药或敏感 )及临床病理的关系。方法　从 1999年 1月至 2 0 0 3年 6月间临床资料及随访资料完整的卵巢癌病例中 ,筛选出 6 0例原发上皮性卵巢癌和 6例正常卵巢作为研究对象。根据临床诊断将其分为 3组 :①化疗耐药组 30例 ,②化疗敏感组 30例 ,③正常卵巢组 6例。全部病例术前均未接受过放疗 ,入院后均行全子宫和双附件切除 +盆腔淋巴结清扫 +阑尾切除 +大网膜切除术 ,6 6例患者均有随访结果。用流式细胞仪定量分析 6 6例标本组织中CX4 3蛋白的表达量。结果　CX4 3蛋白的表达为化疗耐药组 <化疗敏感组 <正常卵巢组织 ,单向方差分析两两比较结果差异有显著意义。结论　CX4 3蛋白表达量的下降与上皮性卵巢癌的化疗耐药显著相关。 Objective To investigate the relationship between CX4 3 and chemosensitivity (drug resistance or sensitivity) and clinicopathologic features of epithelial ovarian cancer. Methods From January 1999 to June 2003 clinical data and follow-up data of complete ovarian cancer cases, 60 cases of primary epithelial ovarian cancer and 6 cases of normal ovary were screened out as the research object. According to clinical diagnosis, they were divided into three groups: ① chemoresistant group 30 cases, ② chemosensitive group 30 cases, ③ normal ovary group 6 cases. All patients had not received preoperative radiotherapy, admission to the hospital after hysterectomy and double attachment dissection + pelvic lymph node dissection + appendectomy + omentum resection, 6 patients were followed up results. Quantitative analysis of CX4 3 protein expression in 6 specimens by flow cytometry. Results The expression of CX4 3 protein was significantly different between chemotherapy-resistant group and chemotherapy-sensitive group